FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products. BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Dublin - Research and Markets (http://www.researchandmarkets.com/research/t99fl5/biomedical_science) has announced the addition of John Wiley and Sons Ltd's new book "Biomedical Sciences: Essential Laboratory Medicine" to their offering. Biomedical Sciences is an indispensable, all encompassing core textbook for first/ second year biomedical science students that will support them throughout their undergraduate career. The book includes the key components of the IBMS accredited degree programmes, plus sections on actual practice in UK hospital laboratories (including the compilation of a reflective portfolio). The book is visually exciting, and written in an interesting and accessible manner while maintaining scientific rigour. Highlighted boxes within the text link the theory to actual clinical laboratory practice for example, the histopathology chapter includes a photographically illustrated flow chart of the progress of a specimen through the histopathology lab, so that students can actually see how the specimen reception/inking/cut-up/cassette/block/section/stain system works, with an emphasis on the safety procedures that ensure specimens are not confused). Key Topics Covered: Chapter 1 Anatomy and physiology of major organ systems Chapter 2 Pathophysiology Chapter 3 Clinical cell biology and genetics Chapter 4 Cellular pathology Chapter 5 Clinical chemistry Read more: Research and Markets: Biomedical Sciences: Essential Laboratory Medicine … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4zkdn4/skeletal_biology_a) has announced the addition of John Wiley and Sons Ltd's new book "Skeletal Biology and Medicine I: Mechanisms Regulating Bone Mass" to their offering. The volume features current basic, clinical, and translational research on aspects of skeletal morphogenesis and remodeling in health and disease. Papers survey vital new insights into the mechanisms of bone development and restructuring, including cellular and mechanical triggers, receptors and signaling pathways. Also covered are the effects of other physiological systems and disease states, such as immune system inflammation, diabetes, infection, and cancer on musculoskeletal health. Recent findings are shaping therapeutic directions that focus on both anti-resorptive and anabolic therapies. Basic scientists, clinical investigators, and clinicians with interests spanning endocrinology, physiology, cell biology, pathology, genetics, molecular biology, rheumatology, oncology, and other areas that relate to bone development and homeostasis will find this a valuable resource for the most recent developments in skeletal biology and medicine. This volume presents manuscripts stemming from the 4th New York Skeletal Biology and Medicine Conference, held at Mount Sinai School of Medicine in New York City on April 27-30, 2011. The papers included in this volume include two of the topic areas presented at the … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will hold an earnings call on Wednesday, May 9th,at 9 a.m. EDT during which it will discuss 2012 first quarter results for the period ended March 31, 2012 and provide a corporate update. Interested parties may access the call live by dialing (888) 264-3177 and using conference ID 72827188. This event is also being streamed via webcast. The webcast is available at http://us.meeting-stream.com/advancedcelltechnology050912. A replay of the call will also be available via the same link. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visitwww.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012. The Company reported a loss from operations of $(5.4) million compared to a loss from operations of $(4.8) million in the 2011 first quarter.ACTreported a net loss of $(5.7) million or $(0.00) per share, compared to a loss in the same period in 2011 of $(3.3) million, or $(0.00) per share. Net cash used in operations for the 2011 first quarter was $4.8 million, compared to net cash used in operations of $3.4 million in the same period in 2011. The Company ended the 2012 first quarter with cash and cash equivalents of $10.8 million, compared to $13.1 million as of December 31, 2011. Highlights from the first quarter of 2012 included: We are very pleased with our progress in the clinic so far, said Chairman and CEO Gary Rabin. We are encouraged by the results we have seen from the early patients treated in each of our indications, and look forward to completing the trials on schedule. Conference call and Webcast The Company will hold a conference call tomorrow … Continue reading →